Comparison of consolidation strategies in acute myeloid leukemia: high-dose cytarabine alone versus intermediate-dose cytarabine combined with anthracyclines

[1]  Lars Kjeldsen,et al.  Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Schmitz,et al.  High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  B. Löwenberg.  Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. , 2013, Blood.

[4]  Peter G. Smith,et al.  Drug Efflux Transporters and Multidrug Resistance in Acute Leukemia: Therapeutic Impact and Novel Approaches to Mediation , 2012, Molecular Pharmacology.

[5]  P. Malani.  Harrison’s Principles of Internal Medicine , 2012 .

[6]  J. Bourhis,et al.  Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study. , 2011, Blood.

[7]  N. Schmitz,et al.  Cytarabine dose of 36 g/m² compared with 12 g/m² within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Naoe,et al.  A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults : the JALSG AML 201 Study , 2011 .

[9]  H. Döhner,et al.  High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.

[10]  J. Karp,et al.  Novel postremission strategies in adults with acute myeloid leukemia , 2009, Current opinion in hematology.

[11]  C. Galmarini,et al.  Problems Related to Resistance to Cytarabine in Acute Myeloid Leukemia , 2004, Leukemia & lymphoma.

[12]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. D. de Vries,et al.  The Role of Drug Efflux Pumps in Acute Myeloid Leukemia , 2002, Leukemia & lymphoma.

[14]  J. Marie.  Drug resistance in hematologic malignancies , 2001, Current opinion in oncology.

[15]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[16]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[17]  N. Nissen,et al.  Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. , 1982, Blood.

[18]  C. Bloomfield,et al.  Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. , 1981, Blood.

[19]  Clinical disciplines.  Cancer and Leukemia Group B , 2010 .

[20]  M. Patnaik,et al.  Anthracycline dose intensification in acute myeloid leukemia. , 2009, The New England journal of medicine.

[21]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.